VRT.CN - Veritas Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.18
+0.01 (+2.86%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close0.17
Open0.18
Bid0.17 x 0
Ask0.18 x 0
Day's Range0.17 - 0.18
52 Week Range0.17 - 1.09
Volume224,530
Avg. Volume135,077
Market Cap13.953M
Beta-2.60
PE Ratio (TTM)N/A
EPS (TTM)-0.16
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire4 days ago

    Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

    VANCOUVER, British Columbia, Aug. 15, 2018-- Veritas Pharma Inc. is pleased to announce that it has signed a Memorandum of Understanding with IsCann Group Limited located in Be'er Tuvya, Israel with the ...

  • GlobeNewswire6 days ago

    Veritas Signs MOU with the Chamber of Commerce, Industry, Services and Tourism Brazil & Puerto Rico

    VANCOUVER, British Columbia, Aug. 13, 2018-- Veritas Pharma Inc. is pleased to announce that it has entered into a Memorandum of Understanding with the Chamber of Commerce, Industry, Services and Tourism ...

  • GlobeNewswire12 days ago

    Frankfurt’s Clearstream Banking Lifts Settlement Restrictions on Securities Active in Medical Cannabis

    VANCOUVER, British Columbia, Aug. 08, 2018-- Veritas Pharma Inc. is pleased to announce that Clearstream Banking, a major central securities depository based in Frankfurt, Germany, which announced on June ...

  • GlobeNewswire23 days ago

    Veritas Pharma Announces Loan to Marapharm and Cancellation of Stock Options

    VANCOUVER, British Columbia, July 27, 2018-- Veritas Pharma Inc. is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options granted under the Company’ ...

  • GlobeNewswirelast month

    Veritas Pharma Signs IP Agreement with UK’s First Medicinal Cannabis Investment Fund

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has signed an Intellectual Property Sharing Agreement (“Joint IP”) with Sativa Investments PLC (“Sativa”) (NEX:SATI), UK’s first medicinal cannabis investment fund. Veritas through its subsidiary company, Cannevert Therapeutics Ltd., will apply its pharmacological methods on cannabis strain lead selection to assist Sativa’s application to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing license.

  • GlobeNewswire2 months ago

    Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed as its business development agent in Cyprus. Currently, medical cannabis is legal in Cyprus, nonetheless doctors may only prescribe it to patients suffering from specific ailments, typically as a last resort and strictly for palliative care.

  • GlobeNewswire2 months ago

    Veritas Pharma Signs R&D and Medical Cannabis Supply Agreement with Colombian Producer Foliumed S.A.S.

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Colombian medical cannabis company Foliumed S.A.S. (“Foliumed”). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical cannabis products with the help of Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”).

  • GlobeNewswire3 months ago

    Veritas Pharma Provides Corporate Update on Q2 2018

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics (“CTL”) signed an agreement with Puerto Rico’s Fundación de Investigación (“FDI”) Clinical Research to perform trials of its lead cannabis strain, CTL-X, to target pain.